Therapies in development for castrate-resistant prostate cancer

Keyphrases

• Castration-resistant Prostate Cancer 100%
• Chemotherapy 100%
• Clinical Research 50%
• Bevacizumab 50%
• Sipuleucel-T 50%
• Ipilimumab 50%
• Immunotherapeutics 50%
• Abiraterone 50%
• Advanced Prostate Cancer 50%
• Epothilones 50%
• Ixabepilone 50%
• Medical Therapy 50%
• Paucity 50%
• Adrenal Androgens 50%
• Calcitriol 50%
• VEGF Inhibitors 50%
• Platinum Analogs 50%
• Satraplatin 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Prostate Cancer 100%
• Clinical Research 50%
• Ixabepilone 50%
• Epothilone 50%
• Bevacizumab 50%
• Sipuleucel T 50%
• Abiraterone 50%
• Calcitriol 50%
• Platinum Derivative 50%
• Vasculotropin Inhibitor 50%
• Satraplatin 50%
• Combination Therapy 50%
• Androgen 50%
• Ipilimumab 50%

Medicine and Dentistry

• Prostate Cancer 100%
• Combination Therapy 50%
• Clinical Research 50%
• Sipuleucel T 50%
• Abiraterone 50%
• Platinum Derivative 50%
• Satraplatin 50%
• Vasculotropin Inhibitor 50%
• Epothilone 50%
• Androgen 50%
• Calcitriol 50%
• Bevacizumab 50%
• Ipilimumab 50%
• Ixabepilone 50%